Introduction {#s0001}
============

Gastric cancer is the fifth most common malignancy globally, and half of all cases occur in Eastern Asia (mainly in China).[@cit0001] Patients with gastric cancer are typically diagnosed with stage IV disease, precluding surgical treatment.[@cit0002] Anemia is one of the common concomitant diseases of advanced gastric cancer (AGC).[@cit0003] The cause is multifactorial,[@cit0004] including hemorrhage, hemolysis, nutritional deficiencies, renal insufficiency, hormonal dysfunction, and other factors. Malignant tumors can cause or aggravate anemia via several mechanisms. In particular, cancer cells destroy hematopoietic cells and inhibit hematopoietic function by infiltrating bone marrow infiltration and reducing peripheral hemoglobin (Hb) levels. Blood loss caused by tumor sites can further aggravate anemia.[@cit0005],[@cit0006] Other reasons include immune-mediated antibody hemolysis and changes in blood clotting capacity.[@cit0007]

Low Hb content is one of the factors affecting the outcomes of pts with AGC. A series of studies confirmed that anemia worsens the prognosis of gastric cancer.[@cit0008],[@cit0009] However, some studies found no correlation between anemia and the outcomes of gastric cancer,[@cit0010],[@cit0011] and thus, the impact of Hb levels on prognosis in pts with AGC receiving first-line chemotherapy remains unclear.

To resolve this issue, our study evaluated the prognostic significance of Hb levels in pts with AGC who have not previously received chemotherapy. Additionally, we explored the relationship between the change of hemoglobin levels following chemotherapy and efficacy in pts with AGC to provide some evidence for improving the prognosis of such pts.

Patients and Methods {#s0002}
====================

Study Population {#s0002-s2001}
----------------

This study was approved by the Ethics Committee of Zhejiang Cancer Hospital and was conducted according to the principles of the Declaration of Helsinki. As this retrospective study did not harm the rights and health of patients and protected their privacy and personal information, the ethics committee waived the requirement to obtain informed consent. In this single-institution retrospective study, we collected data of 397 pts with unresectable locally advanced or metastatic gastric adenocarcinoma who received first-line chemotherapy at Zhejiang Cancer Hospital between 2006 and 2017 ([Figure 1](#f0001){ref-type="fig"}). All pts received at least two cycles of chemotherapy, and measurable lesions were confirmed via imaging. Two hundred and forty-nine consecutive gastric cancer patients were further analyzed. Clinical parameters, including age, gender, Eastern Cooperative Oncology Group performance status, anatomic tumor location, stage of differentiation, Lauren classification, Her-2 expression, liver metastasis, lymph node metastasis, presence of ascites, and initial platelet counts were obtained by reviewing the medical records. [Table 1](#t0001){ref-type="table"} shows the basic characteristics of the selected pts.Table 1Baseline Information on the 249 Patients with Advanced Gastric CancerNNon-Anemic PatientsAnemic Patients*χ*^2^*P* valueN24915297Gender Male15594(61.8%)61(62.9%)0.0270.868 Female9458(38.2%)36(37.1%)Age \<5611575(49.3%)40(41.2%)1.5650.211 ≥5613477(50.7%)57(58.8%)ECOG 0--1217143(94.1%)74(76.3%)16.733\<0.001 2329(5.9%)23(23.7%)Site of gastric Lower8544(28.9%)41(42.3%)5.3790.146 Upper5136(23.7%)15(15.4%) Middle8655(36.2%)31(32.0%) Others2717(11.2%)10(10.3%)Stage of differentiation High-medium4525(16.4%)20(20.6%)1.5360.464 Lower13084(55.3%)46(47.4%) Unclear7443(28.3%)31(32.0%)Lauren classification Diffuse12279(52.0%)43(44.3%)2.1000.350 Intestinal11766(43.4%)51(52.6%) Mixed107(4.6%)3(3.1%)Her-2 Negative7445(29.6%)29(29.9%)2.2430.326 Positive167(4.6%)9(9.3%) Unclear159100(65.8%)59(60.8%)Metastatic sites (Liver) Negative162102(67.1%)60(61.9%)0.7180.397 Positive8750(32.9%)37(38.1%)Metastatic sites (lymph nodes) Negative7451(33.6%)23(23.7%)2.7460.098 Positive175101(66.4%)74(76.3%)Metastatic site (Ascites) Negative197118(77.6%)79(81.4%)0.5210.471 Positive5234(22.4%)18(18.6%)Metastatic site (others) Negative15496(63.2%)58(59.8%)0.2840.594 Positive9556(36.8%)39(40.2%)Initial platelet (10^9^/L) ≤8022(1.3%)0(0.0%)1.2870.522 \>80247150(98.7%)97(100.0%)[^2] Figure 1Flowchart of the patient selection for this study.

Treatment Regimens {#s0002-s2002}
------------------

All of the pts received the first-line doublet treatment, chemotherapy regimens include S-1 40--60 mg twice daily on days 1--14 plus oxaliplatin 130mg/m2 on day 1(N=177, 71.1%), the same dose of S-1 plus cisplatin 60\~80mg/m2 on day 1 (N=27, 10.8%), the same dose of S-1 plus paclitaxel 135--175mg/m2 on day 1 (N=13, 5.2%), capecitabine 1000mg/m2 twice daily on days 1--14 plus oxaliplatin 130mg/m2 on day 1(N=29, 11.7%), docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1 plus fluorouracil 750 mg/m2/d on days 1--5(N=3, 1.2%). The above chemotherapy regimens are all 21 consecutive days per cycle. Treatment was continued until disease progression, intolerable toxicity, or other reason for termination were judged by the physician.

Assessment {#s0002-s2003}
----------

Evaluation of efficacy after 2 cycles of chemotherapy. Tumor response was evaluated according to Response Evaluation Criteria in Solid Tumors 1.1. The objective response rate (ORR) was defined as the percentage of pts who achieved a CR or PR. Statistical analysis of Hb levels was performed using baseline Hb levels before treatment and two cycles after chemotherapy. Anemia was graded according to the National Institute of Cancer Research and Chinese definitions of anemia. Anemia was defined as an Hb level of \<11.0 g/dl in females and \<12.0 g/dl in males.[@cit0012] According to the Common Terminology Criteria for Adverse Events (version 4.0), pts were divided into the non-anemia (normal Hb levels) and anemia group. Then, the anemia group was further divided into mild anemia (10 g/dl to normal levels), moderate anemia (8--10 g/dl), and severe anemia groups (\<8 g/dl).

Medical records or telephone inquiries were used to measure the duration of survival or confirm death. Progression-free survival (PFS) was defined as the time from diagnosis of metastatic disease to first occurrence of PD, or death. Overall survival (OS) was defined as the time from diagnosis of metastatic disease to death from any cause or the last date of follow-up (June 30, 2019). At the end of follow-up, 236 pts had died.

Statistical Analysis {#s0002-s2004}
--------------------

Clinicopathological factors were analyzed using Pearson's *χ*^2^ or Fisher's exact test. The relationship between Hb levels and curative effects was examined using Wilcoxon's signed-rank test and Mann--Whitney's rank-sum *U*-test. PFS and OS were estimated using the Kaplan--Meier method. Univariate analysis (UVA) and multivariate analysis (MVA) by a Cox proportional hazards regression model were used to detect prognostic factors. The statistical significance of survival curves was compared between groups using the Log-rank test. P \< 0.05 denoted statistical significance in all analyses. All data were analyzed using SPSS 20 statistical software (SPSS Inc., Chicago, IL, USA).

Results {#s0003}
=======

Clinical Pathology {#s0003-s2001}
------------------

Among the 249 pts, 152 (61.0%) pts had normal Hb levels, whereas 97 (39.0%) pts had anemia, respectively. Eastern Cooperative Oncology Group performance status of 2 was significantly correlated with anemia (P \< 0.001). No differences were observed between pts with and without anemia in terms of gender, age, site of gastric cancer, stage of differentiation, Lauren classification, Her-2 expression, liver metastasis, lymph node metastasis, presence of ascites, and initial platelet counts ([Table 1](#t0001){ref-type="table"}).

Fourteen (5.6%) pts received red blood cell infusions or erythropoietin treatment, all of whom had severe anemia.

Comparison of Hb Levels Between Pts with and without Anemia {#s0003-s2002}
-----------------------------------------------------------

The Hb levels of pts without anemia before and after chemotherapy were 13.35 ± 1.29 and 11.93 ± 1.50 g/dl, respectively. In order to eliminate the influence of 14 pts treated with blood transfusion or erythropoietin on Hb changes, we analyzed Hb levels of 83 anemia pts. The levels among pts with anemia were 9.83±1.17 g/dl before chemotherapy and 10.22±1.27 g/dl after chemotherapy. ΔHb (difference in Hb levels between before and after chemotherapy) was −1.42 ± 1.45 g/dl among pts without anemia, versus 0.39±1.39 g/dl among pts with anemia (P \< 0.001, [Table 2](#t0002){ref-type="table"}).Table 2Comparison of Hemoglobin (Hb) Levels Between Pts with and without AnemianHb (g/dl)Before ChemotherapyAfter ChemotherapyΔHbNormal group15213.35±1.2911.93±1.50−1.42±1.45Anemia group839.83±1.1710.22±1.270.39±1.39*P* value\<0.001

Relationship Between Hb Levels and Treatment Effects {#s0003-s2003}
----------------------------------------------------

Among the 249 pts, CR, PR, SD and PD were recorded in 3 (1.2%), 109 (43.8%), 124 (49.8%), and 13 pts (5.2%), respectively. The ORR was 47.4% (46/97) for pts with anemia, whereas that for pts without anemia was 43.4% (66/152, P = 0.536). The Hb level before chemotherapy was not correlated with the treatment effect (P = 0.353, [Table 3](#t0003){ref-type="table"}). The Hb levels before and after chemotherapy in the disease control group (CR + PR + SD) were 11.76 ± 2.39 and 11.26 ± 1.67 g/dl, respectively (P \< 0.001), whereas those in the PD group were 12.72 ± 2.10 and 10.79 ± 1.51 g/dl, respectively (P = 0.002). ΔHb was −0.51 ± 1.86 in the disease control group, compared with −1.93 ± 1.33 in the PD group (P = 0.002, [Table 4](#t0004){ref-type="table"}, [Figure 2](#f0002){ref-type="fig"}).Table 3Relationship Between Hemoglobin (Hb) Levels Before Chemotherapy and Treatment EffectsnHb*χ*^2^*P* valueNormalMildModeratelySevereCR320109.0310.353PR1096422176SD12475201514PD1311020 Table 4Relationship Between the Changes of Hemoglobin (Hb) Levels and Treatment EffectsnHb (g/dl)*P* valueBefore ChemotherapyAfter ChemotherapyCR+PR+SD23611.76±2.3911.26±1.67\<0.001PD1312.72±2.1010.79±1.510.002 Figure 2Relationship between the changes of Hb and treatment effects.

Survival Outcomes {#s0003-s2004}
-----------------

The median progression-free survival (mPFS) for all pts was 6.3 months (95% confidence interval \[CI\] = 6.0--6.6). All patients were divided into four groups, including normal, mild, moderate and severe anemia group, mPFS was 6.3, 7.2, 6.1 and 5.7 months, respectively (P=0.121, [Figure 3A](#f0003){ref-type="fig"}). With 10g/l as the cutoff value, mPFS in patients with non-moderate to severe anemia and moderate to severe anemia was 6.5 and 6.1 months (P=0.152, [Figure 3B](#f0003){ref-type="fig"}). With 8g/l as the cutoff value, the mPFS of pts with severe anemia was 5.7 months, which was significantly shorter than that of pts with non-severe anemia (6.4 months, P = 0.036, [Figure 3C](#f0003){ref-type="fig"}).Figure 3Progression-free survival and overall survival of all patients. (**A**) Kaplan-Meier (KM) survival curves comparing the PFS of patients with normal, mild, moderate and severe anemia group.(**B**) Comparing the PFS of patients with non-moderate to severe anemia and moderate to severe anemia group. (**C**) Comparing the PFS of patients with non-severe anemia and severe anemia group. (**D**) Comparing the OS of patients with normal, mild, moderate and severe anemia group. (**E**) Comparing the OS of patients with non-moderate to severe anemia and moderate to severe anemia group. (**F**) Comparing the OS of patients with non-severe anemia and severe anemia group.**Abbreviations:** PFS, progression-free survival; OS, overall survival.

The median overall survival (mOS) of all pts was 14.0 months (95% CI 12.7--15.3), compared with four groups, including normal, mild, moderate and severe anemia group, mOS was 15.0, 15.9, 11.9 and 10.8 months, respectively (P=0.115, [Figure 3D](#f0003){ref-type="fig"}). The mPFS of pts with moderate or severe anemia was 11.5 months, which was significantly shorter than that of pts with non-moderate to severe anemia (15.0 months, P=0.048, [Figure 3E](#f0003){ref-type="fig"}). The mOS was 14.6 months for pts with non-severe anemia, versus 10.8 months for pts with severe anemia (P=0.104, [Figure 3F](#f0003){ref-type="fig"}).

Further analysis of our data, 14 of 20 patients with severe anemia received EPO or transfusion therapy, and 6 patients did not receive the treatment. mPFS was 5.9 and 4.6 months (P=0.40), mOS was 11.0 and 8.9 months (P = 0.43).

Predictors of Mortality {#s0003-s2005}
-----------------------

As for PFS, ascites (P = 0.028) and Hb post chemotherapy (P=0.033) were significantly identified in univariate analysis for PFS ([Table 5](#t0005){ref-type="table"}). In multivariate analysis, ascites (HR=1.374,95% CI: 1.112\~1.636, P =0.041) and decreased Hb post chemotherapy (HR=1.201,95% CI: 1.002\~1.400, P =0.047) were identified as independent prognostic indicators.Table 5Univariate and Multivariate Analysis for PFSVariateNUnivariateMultivariateHRPHRPGender0.668 Male155Reference Female940.944 (0.725\~1.229)Age0.564 \<56115Reference ≥561340.927 (0.717\~1.199)ECOG0.065 0--1217Reference 2321.433 (0.978\~2.100)Site of gastric0.743 Lower85Reference Upper510.389 (0.07\~2.156) Middle860.979 (0.184\~5.209) Others270.732 (0.152\~3.522)Stage of differentiation0.767 High-medium45Reference Lower1301.111 (0.785\~1.574) Unclear741.149 (0.785\~1.682)Lauren classification0.313 Diffuse122Reference Intestinal1170.860 (0.662\~1.118) Mixed101.299 (0.680\~2.481)Her-20.412 Negative74Reference Positive161.334 (0.142\~12.496) Unclear1590.449 (0.120\~1.680)Metastatic sites (Liver)0.228 Negative162Reference Positive871.179 (0.902\~1.541)Metastatic sites (lymph nodes)0.456 Negative74Reference Positive1750.899 (0.680\~1.189)Metastatic site (Ascites)0.0280.041 Negative197ReferenceReference Positive521.421 (1.145\~1.697)1.374 (1.112\~1.636)Metastatic site (others)0.458 Negative154Reference Positive950.905 (0.695\~1.179)Anemia0.21 Normal152Reference Mild420.837 (0.589\~1.188) Moderate351.033 (0.707\~1.510) Severe201.521 (0.937\~2.468)Hb post chemotherapy0.0330.047 Elevated85ReferenceReference Decreased1641.224(1.017\~1.431)1.201 (1.002\~1.400)[^3]

ECOG (P =0.008), ascites (P = 0.001) and Hb post chemotherapy (P=0.031) were significantly identified in univariate analysis for OS ([Table 6](#t0006){ref-type="table"}). In multivariate analysis, ECOG (HR=1.253,95% CI: 1.032\~1.522, P =0.023), ascites (HR=1.689,95% CI: 1.220\~2.339, P =0.002) and decreased Hb post chemotherapy (HR=1.187,95% CI: 1.072\~1.302, P =0.048) were identified as independent prognostic indicators.Table 6Univariate and Multivariate Analysis for OSVariateNUnivariateMultivariateHRPHRPGender0.578 Male155Reference Female940.927(0.711\~1.209)Age0.604 \<56115Reference ≥561340.934(0.723\~1.207)ECOG0.0080.023 0--1217ReferenceReference 2321.739(1.188\~2.546)1.253 (1.032\~1.522)Site of gastric0.259 Lower85 Upper511.073 (0.789\~1.459) Middle860.859 (0.602\~1.225) Others270.697 (0.434\~1.119)Stage of differentiation0.438 High-medium45Reference Lower1301.197 (0845\~1.696) Unclear741.279 (0.874\~1.871)Lauren classification0.211 Diffuse122Reference Intestinal1170.823 (0.633\~1.069) Mixed101.255 (0.656\~2.401)Her-20.281 Negative74Reference Positive160.648 (0.370\~1.134) Unclear1590.988 (0.743\~1.314)Metastatic sites (Liver)0.575 Negative162Reference Positive871.080 (0.826\~1.411)Metastatic sites (lymph nodes)0.775 Negative74Reference Positive1751.042 (0.788\~1.378)Metastatic site (Ascites)0.0010.002 Negative197ReferenceReference Positive521.791 (1.300\~2.466)1.689 (1.220\~2.339)Metastatic site (others)0.22 Negative154Reference Positive950.847 (0.650\~1.104)Anemia0.252 Normal152Reference Mild420.925(0.651\~1.313) Moderate351.274(0.872\~1.861) Severe201.473(0.911\~2.380)Hb post chemotherapy0.0310.048 Elevated85ReferenceReference Decreased1641.274 (1.012\~1.536)1.187 (1.072\~1.302)[^4]

Discussion {#s0004}
==========

Our single-institution retrospective study analyzed the associations of Hb levels with treatment outcomes and survival in 249 pts with AGC who received first-line chemotherapy. Our research demonstrated that Hb levels are associated with prognosis. Pts with PD experience a larger decrease in Hb levels, and those with low Hb levels have a poor prognosis.

The results illustrated that a poor performance status was significantly correlated with anemia, which is consistent with the results of other studies.[@cit0013],[@cit0014] This research demonstrated that Hb levels tended to decrease after treatment in pts without anemia, versus an upward trend in pts with anemia. This finding might be related to adverse reactions to chemotherapy in pts with normal baseline levels of Hb.[@cit0015] In such pts, the drug damages hematopoietic stem cells and causes anemia. Chemotherapy can also damage the kidneys, thereby decreasing the secretion of erythropoietin and inducing anemia.[@cit0016] Meanwhile, among pts without anemia, the tumor inhibits hematopoietic function through the direct invasion of bone marrow. The size of the lesion is reduced by chemotherapy, resulting in improved hematopoietic function and increased Hb levels.

In our study, the ORR of first-line chemotherapy in pts with AGC was 45%, in line with those in the Real-2 study (46.4%)[@cit0017] and SPIRITS trial (31--54%).[@cit0018] There are few reports on the relationship of changes in Hb levels between before and after chemotherapy with efficacy in pts with AGC. Our results illustrated that Hb levels decreased in both the disease control and PD groups. Compared with the findings in the disease control group, Hb levels were significantly decreased in the PD group after treatment. This may be attributed to hypoxic supply of tumor tissue influencing the efficacy of chemotherapy.[@cit0019] This result suggests that changes in Hb levels between before and after chemotherapy can predict treatment efficacy.

The relationship between anemia and treatment outcomes has been described by several authors. Park et al[@cit0008] reported that pts with baseline Hb levels \<10 g/dl had lower response rates and higher risks of death. Ji et al[@cit0020] found that low baseline Hb levels represented an independent negative prognostic factor for OS. However, no correlation between anemia and survival was noted in other studies.[@cit0010],[@cit0011] In terms of ORRs, our study identified no obvious difference between pts with and without anemia. This finding may be related to regional and racial differences and different definitions of anemia. In our study, the median PFS was prolonged in pts with non-severe anemia (Hb≥8 g/dl) compared with severe anemia. Meanwhile, median OS was prolonged in pts with non-anemia and mild anemia (Hb≥10 g/dl) compared with moderate or severe anemia. American Society of Clinical Oncology and American Society of Hematology guidelines[@cit0021] recommended starting anemia treatment when Hb levels are less than 10 g/dl. Our findings suggest that OS and PFS tend to prolong after correcting severe anemia, also numerous reports have demonstrated that correcting anemia can improve patient outcomes,[@cit0022],[@cit0023] effective management of anemia is important for treating gastric cancer.[@cit0024]

The relationship between low baseline Hb levels and poor prognosis in pts with AGC may be attributable to several factors. Anemia reduces oxygen-carrying capacity of the blood, which leads to hypoxia.[@cit0025] Hypoxia can stimulate angiogenesis, which increases tumor aggressiveness.[@cit0026],[@cit0027] Additionally, tumor cells can secrete interleukin-6 and tumor necrosis factor-α, which change the hematopoietic microenvironment and lead to decreases in Hb concentrations.[@cit0028],[@cit0029] Hypoxia can accelerate malignant tumor progression and tumor metastasis through various mechanisms, such as tumor suppressor gene inactivation, changes in gene expression, and clonal selection, thereby increasing resistance to chemotherapy[@cit0030] and ultimately resulting in poor long-term outcomes.

Our study is the largest retrospective study of analyzing the relationship between changes in Hb levels and the efficacy of first-line chemotherapy in patients with advanced gastric cancer. This paper not only analyzes the relationship between baseline hemoglobin and objective response rate, but also discuss the correlation between hemoglobin changes and efficacy. Second, the research demonstrates the correlation between different levels of anemia and survival. However, our study had several limitations. First, this report was a single-center retrospective study with a limited sample size and possible incomplete information, resulting in recall bias. Second, it is difficult to rule out the effects of chemotherapy when assessing the correlation between Hb levels and efficacy. Furthermore, some information relevant to anemia such as iron and vitamin B12 levels were not available, preventing a deeper analysis of pts with anemia. To resolve these problems, prospective research is needed in the future.

Conclusions {#s0005}
===========

Our study found that low baseline Hb levels signify a poor prognosis in pts with advanced gastric cancer. Pts with baseline Hb levels ≥10 g/dl have longer OS. Additionally, pts with disease progression experience larger decreases in Hb level, and the degree of change in Hb levels might be a biomarker for predicting efficacy. Larger samples and more complete data are needed to assess whether early intervention for anemia in pts with advanced gastric cancer can improve prognosis.
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